Please assess the completion status of the following clinical trial:

Trial Title: Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) ≥ 35 kg/m2~* Informed consent~* 70 years of age or less~* Triglyceride level ≤ 200 mg/dL with treatment of 0 or 1 medications~* Blood pressure of ≤ 140/90 mmHg with treatment of 0-2 medications for hypertension~* Fasting blood glucose level of ≤ 110 mg/dL~Exclusion Criteria:~* Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months~* Clinically significant renal, hepatic or psychiatric disease~* Unstable thyroid disease or replacement therapy~* Nephrolithiasis~* Obesity of known genetic or endocrine origin~* Participation in a formal weight loss program or lifestyle intervention~* History of glaucoma or intraocular pressure~* Pregnancy or breastfeeding~* Alcohol abuse~* Smoking cessation within previous 3 months or plans to quit smoking during study~* Eating disorders~* Cholelithiasis within past 6 months~* Excluded medications~* Type 2 diabetes~* Previous bariatric surgery~* History of bipolar disorder or psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Low (Type: EXPERIMENTAL): VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
- VI-0521 Top (Type: EXPERIMENTAL): Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match

Based on this trial design, predict the completion outcome and termination type (if applicable).